Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**deudextromethorphan + quinidine** is a fixed-dose combination drug that contains deudextromethorphan (a deuterated form of dextromethorphan) and quinidine. It is used primarily in the treatment of pseudobulbar affect (PBA), which presents as sudden, uncontrollable episodes of laughing or crying seen in neurological conditions like amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)[1][2][5]. Deudextromethorphan acts as a sigma-1 receptor agonist, a serotonin–norepinephrine reuptake inhibitor, and an NMDA receptor antagonist. Quinidine is included at a low dose to inhibit CYP2D6, thereby increasing plasma concentrations of deudextromethorphan[2][3][5]. The precise mechanism by which this combination benefits PBA is unknown, but these combined actions are thought to modulate emotional expression and neurotransmitter function in the CNS[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on deudextromethorphan + quinidine.